Company Profile
Theravance Biopharma Stock Price, News & Analysis
- Ticker:
- TBPH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
16.92 USD (+0.12%)
Close
Last updated: August 6, 2026
803M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TBPH was little changed and closed at $16.92. No new same-company headline was identified in the current news window.
Company overview
Respiratory Medicines
Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.
YUPELRI
YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Theravance receives collaboration revenue tied to U.S. sales. Following the outcome of the CYPRESS study, the company is winding down that clinical program and restructuring around its commercial asset and remaining strategic opportunities.
Future catalysts
Theravance is in a transition phase after the CYPRESS outcome, and the company is now leaning into restructuring and strategic review work. The key thing to watch is whether the cost action really changes the shape of the business or just buys more time.
Recent news
- 01
- 02
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Theravance Biopharma
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Theravance Biopharma (TBPH)?
Theravance Biopharma (TBPH) most recently closed at 16.92 USD, a +0.12% move versus the previous session.
What is the market cap of Theravance Biopharma (TBPH)?
Theravance Biopharma currently has a market capitalization of 803M USD on BioPharmSignal.
What does Theravance Biopharma do?
Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Theravance receives...
On which exchange is TBPH stock listed?
Theravance Biopharma (TBPH) is associated with NASDAQ, United States, Biopharma.
What is Respiratory?
Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.
Which conditions is Theravance Biopharma targeting with Respiratory?
Theravance Biopharma is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Theravance Biopharma describe recent progress with Respiratory?
Theravance is in a transition phase after the CYPRESS outcome, and the company is now leaning into restructuring and strategic review work. The key thing to watch is whether the cost action really changes the shape of the business or just buys more time.
What is Medicines?
Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.